Clinical Trial Update: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study [Phase 2]

View source ↗

Summary

A multicenter Phase II trial evaluating sintilimab plus chidamide for relapsed and refractory cutaneous T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Cutaneous T-cell Lymphoma | Phase 2 | Status: UNKNOWN